SynthesisBMC cancer2025
Optimal intrapleural therapy with alpha-hemolytic streptococci bio-product (Mannatide) in controlling malignant pleural effusion: a clustered systematic review and meta-analysis.
Synthesis in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundMannatide is an alpha-hemolytic streptococci bio-product. We conducted a comprehensive clustered systematic review and meta-analysis to reveal the clinical values of Mannatide for controlling malignant pleural effusion (MPE), identify the optimal therapeutic regimens, indications and usage, and assess their clinical effectiveness and safety.
methodsWe collected all eligible studies from both Chinese and English databases and clustered them into homogeneous comparisons or therapeutic regimens. We evaluated the risk of bias in eligible studies using RoB 2, pooled the data from each regimen using Review Manager 5.4, and summarized the quality of evidence.
resultsSeventy-eight studies met the eligibility criteria. Among six comparisons of perfusion with sclerosant alone, Mannatide showed only better complete response of MPE and lower pleurodesis failure and disease progression than interleukin-2. Among twelve combination therapeutic regimens, Mannatide and cisplatin might significantly improve the complete response (2.46, 2.07 to 2.91) and result in a low pleurodesis failure (0.28, 0.23 to 0.33) and disease progression (0.32, 0.21 to 0.48). For MPE with primary treatment, moderate to massive effusion, Karnofsky Performance Status ≥ 40 to 60 or anticipated survival time ≥ two to three months, perfusion with Mannatide at 20 to 50 mg/time, once per week and two to four times and cisplatin at 30 to 60 mg/time might achieve ideal clinical response. Most outcomes were moderate to low quality.
conclusionMannatide may be a potential pleural sclerosant, which combination with cisplatin may represent a preferred therapeutic approach with a good clinical response and safety in controlling MPE.
trial registrationPROSPERO CRD42022338798.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.